BR112012028920A2 - formulações de anticorpo de alta concentração - Google Patents

formulações de anticorpo de alta concentração

Info

Publication number
BR112012028920A2
BR112012028920A2 BR112012028920A BR112012028920A BR112012028920A2 BR 112012028920 A2 BR112012028920 A2 BR 112012028920A2 BR 112012028920 A BR112012028920 A BR 112012028920A BR 112012028920 A BR112012028920 A BR 112012028920A BR 112012028920 A2 BR112012028920 A2 BR 112012028920A2
Authority
BR
Brazil
Prior art keywords
high concentration
antibody formulations
concentration antibody
formulations
antisclerostin
Prior art date
Application number
BR112012028920A
Other languages
English (en)
Other versions
BR112012028920B1 (pt
Inventor
D Osslund Timothy
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012028920(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112012028920A2 publication Critical patent/BR112012028920A2/pt
Publication of BR112012028920B1 publication Critical patent/BR112012028920B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

formulações de anticorpo de alta concentração. neste documento estão divulgadas formulações de anticorpo de alta concentração compreendendo uma imunoglobulina antiesclerostina e um sal de acetato e/ou tampão de acetato e métodos de utilização.
BR112012028920-9A 2010-05-14 2011-05-11 Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína BR112012028920B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33498610P 2010-05-14 2010-05-14
US61/334,986 2010-05-14
PCT/US2011/036062 WO2011143307A1 (en) 2010-05-14 2011-05-11 High concentration antibody formulations

Publications (2)

Publication Number Publication Date
BR112012028920A2 true BR112012028920A2 (pt) 2017-03-14
BR112012028920B1 BR112012028920B1 (pt) 2021-03-23

Family

ID=44146975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012028920-9A BR112012028920B1 (pt) 2010-05-14 2011-05-11 Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína

Country Status (29)

Country Link
US (4) US9352043B2 (pt)
EP (3) EP2569010B1 (pt)
JP (6) JP5889877B2 (pt)
KR (3) KR102220879B1 (pt)
CN (1) CN102946903B (pt)
AU (1) AU2011250920B2 (pt)
BR (1) BR112012028920B1 (pt)
CA (1) CA2798888C (pt)
CL (1) CL2012003172A1 (pt)
CO (1) CO6640258A2 (pt)
CY (2) CY1119069T1 (pt)
DK (2) DK2569010T3 (pt)
EA (3) EA027039B1 (pt)
ES (2) ES2773031T3 (pt)
HN (1) HN2012002446A (pt)
HR (2) HRP20170983T1 (pt)
HU (2) HUE033315T2 (pt)
IL (3) IL264636B (pt)
LT (2) LT3195880T (pt)
ME (1) ME02819B (pt)
MX (1) MX2012013268A (pt)
PL (2) PL2569010T3 (pt)
PT (2) PT2569010T (pt)
RS (2) RS56210B1 (pt)
SG (3) SG10201912670XA (pt)
SI (2) SI2569010T1 (pt)
TW (4) TWI689517B (pt)
WO (1) WO2011143307A1 (pt)
ZA (1) ZA201208543B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2008118970A2 (en) 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
CN102946903B (zh) * 2010-05-14 2014-11-26 安进公司 高浓度抗体制剂
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
SG11201403718YA (en) * 2011-12-28 2014-07-30 Amgen Inc Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
MA37777B1 (fr) * 2012-06-21 2017-07-31 Ucb Pharma Sa Préparation pharmaceutique
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
KR102651018B1 (ko) 2013-09-11 2024-03-27 이글 바이오로직스 인코퍼레이티드 점도저하제를 함유하는 액체 단백질 제형
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US9527922B2 (en) 2014-12-31 2016-12-27 Development Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
WO2016108894A1 (en) * 2014-12-31 2016-07-07 Develpment Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
TW201726111A (zh) * 2015-09-30 2017-08-01 持田製藥股份有限公司 含高濃度抗體之液體製劑
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2019007916A (es) 2016-12-29 2019-12-05 Univ Miami Metodo para modular la actividad de inflamasoma e inflamacion en el pulmon.
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US11590237B2 (en) * 2017-05-18 2023-02-28 Merck Sharp & Dohme Llc Pharmaceutical formulation comprising incretin-insulin conjugates
EP3659586B1 (en) * 2017-07-27 2023-06-21 Jiangsu Hengrui Medicine Co., Ltd. Sost antibody pharmaceutical composition and uses thereof
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
JP6544669B1 (ja) 2018-03-16 2019-07-17 ディヴェロップメント センター フォー バイオテクノロジー アルファエノラーゼに特異的な抗体及びその使用
AU2019243595A1 (en) * 2018-03-30 2020-09-17 Amgen Inc. C-terminal antibody variants
WO2020010273A1 (en) * 2018-07-03 2020-01-09 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
WO2020028401A1 (en) * 2018-07-31 2020-02-06 Amgen Inc. Pharmaceutical formulations of masked antibodies
MA53272A (fr) * 2018-08-10 2021-11-17 Amgen Inc Procédé de préparation d'une formulation pharmaceutique d'anticorps
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
CN114703067B (zh) * 2022-04-06 2023-09-05 上海光玥生物科技有限公司 一种光合微生物及其用途和质粒

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
JPS5889877A (ja) 1981-11-21 1983-05-28 Nippon Telegr & Teleph Corp <Ntt> 超伝導回路装置
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
JPH06502311A (ja) 1990-10-22 1994-03-17 フォックス・チェイス・キャンサー・センター Ｒｎａ療法を提供するためのｄｎａ構造
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
TW205553B (pt) 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
AU700371B2 (en) 1993-06-07 1999-01-07 Genentech Inc. Hiv envelope polypeptides
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
EP0756628B1 (en) 1994-04-29 2007-11-14 Curis, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
WO1996039486A1 (en) 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human ccn-like growth factor
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
WO1997044461A2 (en) 1996-05-22 1997-11-27 Novopharm Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
CA2297109A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
PT1133558E (pt) 1998-11-27 2007-01-31 Ucb Sa Composições e métodos para aumentar a mineralização óssea
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP1151002A4 (en) 1999-01-29 2002-05-02 Imclone Systems Inc KDR-SPECIFIC ANTIBODIES AND USES THEREOF
ATE440109T1 (de) 1999-06-09 2009-09-15 Genentech Inc Methoden zur diagnose von tumoren
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
JP4141095B2 (ja) 1999-10-29 2008-08-27 三洋電機株式会社 半導体装置とその製造方法
EP1266000A1 (en) 2000-03-02 2002-12-18 Amgen Inc. Chordin-like-2 molecules and uses thereof
US20020106650A1 (en) 2000-06-01 2002-08-08 Paszty Christopher J. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
US20040132021A1 (en) 2000-06-19 2004-07-08 Wendy Balemans Osteolevin gene polymorphisms
AU2002216610A1 (en) 2000-09-01 2002-04-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1324776B2 (en) * 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
BR0214680A (pt) 2001-12-06 2006-05-30 Biocontrol Systems Inc coleta de amostra e sistema de teste
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
WO2003073991A2 (en) 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
AU2003251592A1 (en) 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
JP4976653B2 (ja) 2002-11-01 2012-07-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス 免疫刺激性ＣｐＧオリゴヌクレオチドを用いてバイオテロ病原体による感染症を予防する方法
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
US7226902B2 (en) 2003-03-14 2007-06-05 Celltech R&D, Inc. Ligands for TGF-beta binding proteins and uses thereof
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
EP1786837B1 (en) 2004-08-04 2013-05-01 Amgen Inc., Antibodies to dkk-1
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
EP1981910B1 (en) 2006-01-13 2013-06-26 A Chan Holding B.V. Method for identifying inhibitor of the glypican-sclerostin interaction
EP2094731A2 (en) 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
WO2008061013A2 (en) 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
FI3345607T3 (fi) 2006-12-29 2022-11-30 Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia
JP2010526766A (ja) 2007-02-02 2010-08-05 ノバルティス アーゲー 骨関連障害を処置するためのスクレロスチン結合パートナーのモジュレーター
BRPI0809026A2 (pt) 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
ES2560532T3 (es) 2007-11-02 2016-02-19 Novartis Ag Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
BRPI0819688A2 (pt) * 2007-12-14 2015-06-16 Amgen Inc Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
JP5642065B2 (ja) * 2008-05-23 2014-12-17 ノボ ノルディスク ヘルス ケア アーゲー ペグ化されたｇｌａ−ドメイン含有タンパク質を含む低粘度組成物
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
CN102946903B (zh) * 2010-05-14 2014-11-26 安进公司 高浓度抗体制剂
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
MX354481B (es) 2010-10-27 2018-03-07 Amgen Inc Anticuerpos dkk1 y métodos de uso.
RS57038B1 (sr) * 2010-11-17 2018-05-31 Chugai Pharmaceutical Co Ltd Multi-specifičan antigen-vezujući molekul koji ima alternativnu funkciju funkciji faktora viii koagulacije krvi
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody

Also Published As

Publication number Publication date
US10064946B2 (en) 2018-09-04
KR101861867B1 (ko) 2018-05-29
EA027039B1 (ru) 2017-06-30
EA201291226A1 (ru) 2013-04-30
TW202017941A (zh) 2020-05-16
DK2569010T3 (en) 2017-06-26
JP2022000436A (ja) 2022-01-04
SG185465A1 (en) 2012-12-28
PT3195880T (pt) 2020-02-21
JP6174176B2 (ja) 2017-08-02
AU2011250920B2 (en) 2015-05-21
KR20130117650A (ko) 2013-10-28
KR102220879B1 (ko) 2021-02-26
TWI617570B (zh) 2018-03-11
JP2016138110A (ja) 2016-08-04
IL264636B (en) 2022-09-01
JP2013527176A (ja) 2013-06-27
AU2011250920A1 (en) 2012-12-20
EA201692242A1 (ru) 2017-11-30
MX2012013268A (es) 2013-05-28
HRP20170983T1 (hr) 2017-09-22
US20190022230A1 (en) 2019-01-24
TWI689517B (zh) 2020-04-01
CA2798888C (en) 2019-10-01
EA037392B1 (ru) 2021-03-23
DK3195880T3 (da) 2020-03-02
IL295275A (en) 2022-10-01
LT2569010T (lt) 2017-08-10
SI2569010T1 (sl) 2017-09-29
JP7267707B2 (ja) 2023-05-02
ME02819B (me) 2018-01-20
EP3195880B1 (en) 2019-11-27
JP6416336B2 (ja) 2018-10-31
JP5889877B2 (ja) 2016-03-30
JP2019031515A (ja) 2019-02-28
EP2569010B1 (en) 2017-04-12
TW202241510A (zh) 2022-11-01
ES2773031T3 (es) 2020-07-09
PL2569010T3 (pl) 2017-09-29
RS56210B1 (sr) 2017-11-30
PT2569010T (pt) 2017-05-31
IL223014A0 (en) 2013-02-03
HN2012002446A (es) 2015-08-03
ES2626033T3 (es) 2017-07-21
RS59993B1 (sr) 2020-04-30
US11040102B2 (en) 2021-06-22
KR102026038B1 (ko) 2019-09-26
TWI759634B (zh) 2022-04-01
SG10201912670XA (en) 2020-02-27
HUE033315T2 (en) 2017-11-28
KR20180056803A (ko) 2018-05-29
JP2023182702A (ja) 2023-12-26
US20130202620A1 (en) 2013-08-08
BR112012028920B1 (pt) 2021-03-23
US9352043B2 (en) 2016-05-31
EP3620175A1 (en) 2020-03-11
US20210275671A1 (en) 2021-09-09
SG10201701869YA (en) 2017-04-27
KR20190109600A (ko) 2019-09-25
ZA201208543B (en) 2021-10-27
EP3195880A1 (en) 2017-07-26
CY1122669T1 (el) 2021-03-12
IL264636A (pt) 2019-03-31
TW201706304A (zh) 2017-02-16
US20160235849A1 (en) 2016-08-18
CY1119069T1 (el) 2018-01-10
JP2017222674A (ja) 2017-12-21
CO6640258A2 (es) 2013-03-22
CL2012003172A1 (es) 2013-11-29
LT3195880T (lt) 2020-01-10
HUE047492T2 (hu) 2020-04-28
TW201144326A (en) 2011-12-16
HRP20200268T1 (hr) 2020-05-29
EA202092884A1 (ru) 2022-01-31
EP2569010A1 (en) 2013-03-20
CN102946903B (zh) 2014-11-26
PL3195880T3 (pl) 2020-06-01
SI3195880T1 (sl) 2020-03-31
CA2798888A1 (en) 2011-11-17
WO2011143307A1 (en) 2011-11-17
IL223014B (en) 2019-02-28
CN102946903A (zh) 2013-02-27

Similar Documents

Publication Publication Date Title
BR112012028920A2 (pt) formulações de anticorpo de alta concentração
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
CY1123145T1 (el) Anti-cd40 αντισωματα
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
EA201300239A1 (ru) Антитела к fap и способы их применения
EA201491224A1 (ru) Анти-псф-тау-антитела и их применение
CL2015000582A1 (es) Anticuerpos anti-mcam y métodos asociados de uso
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
UA116873C2 (uk) Антитіло, яке зв&#39;язується з ox40
EP2970508A4 (en) GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE
BR112014028600A2 (pt) formulações de anticorpo monoclonal de alta concentração
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
DK2637690T3 (da) Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration
EA201171494A1 (ru) Миметики белка smac
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201401065A1 (ru) Ang2-связывающие молекулы
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
MX336109B (es) Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
EA201390467A1 (ru) Композиции антител и способы применения

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2011, OBSERVADAS AS CONDICOES LEGAIS.